DLX-105

N/A

Report date: 2022/07/19 20:00:45

Base Information

Drug NameDLX-105
Drug Alias NameDLX-105ESBA-105
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody fragment > Single-chain FV antibody fragment (scFv)
Mechanisms of ActionTumor necrosis factor α inhibitors
TargetsTumor necrosis factor α
Therapy Area/IndicationsPsoriasisUveitis, AnteriorDry Eye Syndromes +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesAustriaGermany +[4] 
CombinationsNo
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesEsbatech Ag
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesEsbatech AgDelenex Therapeutics AgAlcon
Active IndicationsN/A
Inactive IndicationsPsoriasisUveitis, AnteriorDry Eye Syndromes +[5] 

Other Information

ATC CodeN/A
Related LinksN/A